EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. announced today that it has initiated a study to evaluate a new autologous skin care crème. The study, being conducted under the supervision of David McDaniel, MD at the McDaniel Institute of Anti-Aging Research, Virginia Beach, VA, will assess the impact of the crème on mild to severe photo-damaged skin.
“For the first time, we would be able to offer our patients an autologous crème that has been exclusively created for them using media enriched by their own fibroblast cells.”
“If successful, this would be a significant breakthrough because it would create an entirely new product category,” said Dr. McDaniel. “For the first time, we would be able to offer our patients an autologous crème that has been exclusively created for them using media enriched by their own fibroblast cells.” The first patients in the study are now being treated with the crème.
“This is an important business development for us because it expands our aesthetic franchise,” said David Pernock, Chief Executive and Chair, Fibrocell Science. “In essence, it’s a designer crème.”
The crème is based on the Company’s sophisticated scientific fibroblast platform and patents have been filed. Results of the study are expected in May. The Fibrocell Science Autologous Crème will be commercially available exclusively from Fibrocell certified physicians later this year.
About Fibrocell Science, Inc.
Fibrocell Science, Inc. (FCSC) is an autologous cellular therapeutic company focused on the development of innovative products for aesthetic, medical and scientific applications. Fibrocell Science, Inc. is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well as its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com.
All statements in this press release that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, without limitation, the Company’s ability to complete the study by May 2013 and make the crème commercially available later this year. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of the Company’s control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011, as updated in “Item 1A. Risk Factors” in the Company’s Quarterly Reports on Form 10-Q filed since the annual report. The Company operates in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. The Company disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company’s public filings with the SEC.